GlaxoSmithKline
After China, Iraq, Poland, GSK bribery probe now expands to Jordan, Lebanon
17 Apr 2014
The probe into a whistle-blower's allegations that British drug giant GlaxoSmithKline’s employees bribed doctors to prescribe its products has now expanded to the Middle East
After China and Iraq, GSK now faces bribery probe in Poland
14 Apr 2014
British drug giant GlaxoSmithKline (GSK), is under a criminal probe for allegedly bribing doctors in Poland for prescribing its asthma drug Seretide
GSK spends $1.05 bn to raise stake in Indian arm
11 Mar 2014
GlaxoSmithKline Plc (GSK) yesterday said that it has paid £625 million ($1.05 billion) to increase its stake in its Indian subsidiary GSK Pharmaceuticals to 75 per cent
GlaxoSmithKline to stop paying doctors for product promotion
17 Dec 2013
The move comes after the biggest drugmaker in the UK stood accused of making corrupt payments to doctors and officials to boost its drug sales in China
Glaxo announces open offer to hike stake in Indian arm
16 Dec 2013
Betting on rising drug demand, GlaxoSmithKline Plc has earmarked around $1 billion to raise its stake in its Indian subsidiary to 75 per cent
GSK sells thrombosis drugs to Aspen for $1.13 billion
01 Oct 2013
The sale comes a month after London-based GSK agreed to sell its Lucozade and Ribena soft drink brands to Japan's Suntory Beverages for £1.35 billion
Japan's Suntory to pay $2.11 bn for GSK’s Lucozade, Ribena soft drink brands
10 Sep 2013
Japan's Suntory Beverage & Food Ltd yesterday agreed to buy the Lucozade and Ribena brands from GlaxoSmithKline Plc, for £1.35 billion in order to expand its soft drinks portfolio in Europe
India revokes patent of GSK’s breast cancer drug Tykerb
02 Aug 2013
The Intellectual Property Appellate Board, however, upheld the patent granted to the drug’s active pharmaceutical ingredient `lapatinib`
China accuses GSK of bribery, raising prices and tax fraud
11 Jul 2013
Employees of GSK in China have confessed to bribing doctors, hospitals, government officials and others to prescribe the company's medicines to increase drug sales, China's ministry of public security said in a website statement
China launches probe on GSK over price fixing
05 Jul 2013
GSK accused of paying off rivals to delay entry of generic drugs
19 Apr 2013
The UK regulator today said that GSK has made substantial payments to three smaller rivals to stop them from releasing generic versions of its paroxetine anti-depressant drug Seroxat
Featured articles
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation